KaydedilenlerDerginizi ekleyin

Dergiler / Turkish Journal of Biology / 2013 / Cilt: 37 - Sayı: 4

Stimulation of dendritic cells with vaccine and vaccine antibody complex and effect on immune response

İbrahim HATİPOĞLU
İbrahim SÖĞÜT
Soner AKSU
Duygu ERCAN
Aynur BAŞALP
Hülya SİVAS
Sayfa
457–463
Yayın Tarihi
2022-10-17
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Our results showed that commercial HBV vaccine loaded DCs induced humoral response in HBV-tg mice but had no effect on cellular immunity.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Dendritic cell (DC) vaccines are a promising and potent therapeutic tool for chronic diseases, autoimmune diseases, and cancer because of the unique ability of DCs to stimulate T cells.
📊
Temel Bulgular & Veri:DCs were derived from the bone marrow of transgenic hepatitis B (HBV-tg) mice using a granulocyte macrophage-colony stimulating factor and interleukin-4, and then loaded with a commercial HBV vaccine (containing hepatitis B virus surface antigens and aluminum hydroxide adjuvant) or a vaccine antibody complex.
💡
Sonuç & Katkı:Our results showed that commercial HBV vaccine loaded DCs induced humoral response in HBV-tg mice but had no effect on cellular immunity.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Dendritic cell (DC) vaccines are a promising and potent therapeutic tool for chronic diseases, autoimmune diseases, and cancer because of the unique ability of DCs to stimulate T cells. The challenge of DC vaccines is to find an effective form for antigen presentation. Although pure antigens, antigen complexes, plasmids, and mRNA have been used in different studies, no proper application to overcome this problem has been found yet. In this study, we investigated the eligibility of a commercial hepatitis B virus (HBV) vaccine or a vaccine monoclonal antibody complex for antigen loading of DCs for a therapeutic purpose. DCs were derived from the bone marrow of transgenic hepatitis B (HBV-tg) mice using a granulocyte macrophage-colony stimulating factor and interleukin-4, and then loaded with a commercial HBV vaccine (containing hepatitis B virus surface antigens and aluminum hydroxide adjuvant) or a vaccine antibody complex. HBV-tg mice were immunized with the vaccine and vaccine antibody loaded DCs. Optimum HBV vaccine concentration and loading time were determined by 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium (WST- 1) methods. Therapeutic effects of vaccine antibody loaded DCs were determined by the evaluation of antibody response and hepatitis B surface expression levels in HBV-tg mice. Our results showed that commercial HBV vaccine loaded DCs induced humoral response in HBV-tg mice but had no effect on cellular immunity.

🔖

Bu Makaleye Atıf Yap

HATİPOĞLU, İ., SÖĞÜT, İ., AKSU, S., ERCAN, D., BAŞALP, A., SİVAS, H. (2022). Stimulation of dendritic cells with vaccine and vaccine antibody complex and effect on immune response. Turkish Journal of Biology, Cilt: 37 - Sayı: 4, 457–463. https://ajindex.com/articles/600474

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (10)

  1. Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med 137: 1142–62, 1973.
  2. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 392: 245–52, 1998.
  3. Ardavin C, Martinez del Hoyo G, Martin P et al. Origin and differentiation of dendritic cells. Trends Immunol 22: 691–700, 2001.
  4. Wykes M, Pombo A, Jenkins C et al. Dendritic cells interact directly with naive B lymphocytes to transfer antigen and initiate class switching in a primary T-dependent response. J Immunol 161: 1313–19, 1998.
  5. Cella M, Scheidegger D, Palmer-Lehmann K et al. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 184: 747–52, 1996.
  6. Brasel K, De Smedt T, Smith JL et al. Generation of murine dendritic cells from flt3-ligand-supplemented bone marrow cultures. Blood 96: 3029–39, 2000.
  7. Shimizu Y, Guidotti LG, Fowler P et al. Dendritic cell immunization breaks cytotoxic T lymphocyte tolerance in hepatitis B virus transgenic mice. J Immunol 161: 4520–29, 1998.
  8. Spranger S, Javorovic M, Burdek M et al. Generation of Th1- polarizing dendritic cells using the TLR7/8 agonist CL075. J Immunol 185: 738–47, 2010. FDA. Approval Letter – Provenge, 2010. Food and Drug Administration. Washington DC; 2010. Available at http://www. fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ ApprovedProducts/ucm210215.htm WHO. Hepatitis B vaccines WHO position paper, 2006. World Health Organization. Geneva; 2006. Available at http://www. who.int/immunization/topics/WHO_position_paper_HepB. pdf. WHO. Hepatitis B, 2000. World Health Organization. Geneva; 2000. Available at http://www.who.int/mediacentre/factsheets/ fs204/en/. Michel ML, Deng Q, Mancini-Bourgine M. Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges. J Hepatol 54: 1286–96, 2011. Dienstag JL. Hepatitis B virus infection. N Engl J Med 359: 1486–1500, 2008.
  9. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t) ide analogues. Gastroenterology 137: 1593–1608, 2009.
  10. Furukawa S, Akbar SMF, Hasabe A et al. Production of hepatitis B surface antigen-pulsed dendritic cells from immunosuppressed murine hepatitis B virus carrier: evaluation of immunogenenicity of antigen-pulsed dendritic cells in vivo. Immunobiology 209: 551–57, 2004. Jiang WZ,